Literature DB >> 2894835

Polyclonal integration of HTLV-I proviral DNA in lymphocytes from HTLV-I seropositive individuals: an intermediate state between the healthy carrier state and smouldering ATL.

K Yamaguchi1, T Kiyokawa, K Nakada, L S Yul, N Asou, T Ishii, I Sanada, M Seiki, M Yoshida, E Matutes.   

Abstract

We have studied 15 individuals (aged 14-74 years) with antibodies to HTLV-I in their serum and random integration of HTLV-I proviral DNA in their peripheral blood lymphocytes. All but one of these patients suffered from a variety of non-specific complaints which did not correspond to those of adult T-cell leukemia (ATL). All of them were born in Kyushu and Okinawa which are endemic areas for HTLV-I infection; 25% of their family members were also seropositive for HTLV-I. The only haematological abnormality in these patients was the presence of few atypical lymphoid cells in the peripheral blood. The CD4/CD8 ratios were normal but the proportion of Tac positive cells was slightly higher than normal. These individuals with polyclonal integration of HTLV-I proviral DNA seem to represent an intermediate state between smouldering ATL (monoclonal integration) and healthy HTLV-I carriers (with antibodies but no detectable HTLV-I proviral DNA). Patients with this intermediate state of HTLV-I infection may be at risk to progress to ATL. The natural history of HTLV-I infection in humans leading to the development of ATL is reviewed in the light of these new findings.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2894835     DOI: 10.1111/j.1365-2141.1988.tb06185.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  9 in total

Review 1.  The epidemiology of HTLV-I infection.

Authors:  N Mueller
Journal:  Cancer Causes Control       Date:  1991-01       Impact factor: 2.506

2.  Constitutive IL-2 expression in HTLV-I-infected leukaemic T cell lines.

Authors:  J P Farcet; F Lebargy; C Lavignac; P Gaulard; A Dautry; L Gazzolo; P H Roméo; W Vainchenker
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

3.  High human T cell leukemia virus type-1(HTLV-1) provirus load in patients with HTLV-1 carriers complicated with HTLV-1-unrelated disorders.

Authors:  Daisuke Sasaki; Yuko Doi; Hiroo Hasegawa; Katsunori Yanagihara; Kunihiro Tsukasaki; Masako Iwanaga; Yasuaki Yamada; Toshiki Watanabe; Shimeru Kamihira
Journal:  Virol J       Date:  2010-04-28       Impact factor: 4.099

4.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

5.  Adult T-cell leukemia: a review of epidemiological evidence.

Authors:  Masako Iwanaga; Toshiki Watanabe; Kazunari Yamaguchi
Journal:  Front Microbiol       Date:  2012-09-10       Impact factor: 5.640

6.  Adult T-cell leukemia in spouses.

Authors:  I Sanada; K Yamaguchi; M Yoshida; T Ishii; A Tsukamoto; M Sato; S Obata; T Shido
Journal:  Jpn J Cancer Res       Date:  1989-05

7.  Haematology and blood chemistry in free-ranging quokkas (Setonix brachyurus): Reference intervals and assessing the effects of site, sampling time, and infectious agents.

Authors:  Pedro A Martínez-Pérez; Timothy H Hyndman; Patricia A Fleming
Journal:  PLoS One       Date:  2020-09-17       Impact factor: 3.240

8.  The CD3 versus CD7 plot in multicolor flow cytometry reflects progression of disease stage in patients infected with HTLV-I.

Authors:  Seiichiro Kobayashi; Yamin Tian; Nobuhiro Ohno; Koichiro Yuji; Tomohiro Ishigaki; Masamichi Isobe; Mayuko Tsuda; Naoki Oyaizu; Eri Watanabe; Nobukazu Watanabe; Kenzaburo Tani; Arinobu Tojo; Kaoru Uchimaru
Journal:  PLoS One       Date:  2013-01-22       Impact factor: 3.240

9.  Mortality among inhabitants of an HTLV-I endemic area in Japan.

Authors:  K Iwata; S Ito; H Saito; M Ito; M Nagatomo; T Yamasaki; S Yoshida; H Suto; K Tajima
Journal:  Jpn J Cancer Res       Date:  1994-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.